智通财经APP讯，金斯瑞生物科技(01548)发布公告，于2024年11月5日，传奇生物宣布将展示有关3期 CARTITUDE-4试验的微小残留病(MRD)阴性率的最新数据，该试验对比CARVYKTI®(西达基奥仑赛，cilta-cel)与标准疗法(SoC)针对多发性骨髓瘤患者的治疗。研究评估了既往接受过 1–3线治疗且来那度胺耐药的患者，并将在2024年12月9日(星期一)下午5:45(太平洋时间)于圣地亚哥举办的第66届美国血液学会年会上以口头报告形式公布。
来自CARTITUDE-4的数据支持美国食品药品监督管理局及欧盟委员会在今年早些时候批准CARVYKTI®用于治疗复发或难治性多发性骨髓瘤成人患者，这些患者既往至少接受过一线治疗(LOT)，包括一种蛋白酶体抑制剂(PI)和一种免疫调节剂(IMiD)且对来那度胺耐药。CARVYKTI®是目前首个且唯一获批用于治疗既往至少接受过一线治疗的多发性骨髓瘤患者的靶向BCMA的CAR-T细胞疗法。CARVYKTI目前已在全球五个国家商业化，有超过4,000名患者使用。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.